A real-world study assessing the safety and efficacy of venetoclax-based regimens in relapsed refractory myeloma (RRMM) or amyloidosis (RRAL)
Latest Information Update: 17 Jul 2020
At a glance
- Drugs Venetoclax (Primary) ; Antineoplastics; Levofloxacin
- Indications Amyloidosis; Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association